Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2016

View Archived Issues

HSRx-431 shows efficacy against Zika virus

Laminin subunit gamma-2 as a novel biomarker for early diagnosis of hepatocellular carcinoma

PPMF-1 methylation is predictive of sunitinib response in kidney cancer

Serum tumor marker panel identifies lung cancer and subtypes

Ono submits sNDA in Japan for Kyprolis for relapsed or refractory multiple myeloma

Opdivo intravenous infusion approved in Japan for treatment of unresectable or metastatic RCC

Moderna Therapeutics closes equity financing to support continued growth

Aralez Pharmaceuticals obtains rights to Zontivity in U.S. and Canada

Plex Pharmaceuticals wins NIH Phase I SBIR grant

First patients enrolled in Jounce Therapeutics' ICONIC study

La Jolla reports phase I results for LJPC-401, outlines pivotal study plans

Sensorion reports results from phase I study of SENS-218 for inner ear lesions

FDA grants QIDP status to Matinas Biopharma's MAT-2203

Repros Therapeutics reports phase II findings for oral Proellex in endometriosis

TAXIS Pharmaceuticals' TXA-709 earns FDA QIDP designation

FDA grants priority review to sBLA for Keytruda as first-line treatment for NSCLC

Cantabio Pharmaceuticals, Cambridge Enterprise enter agreement for tau protein-targeting candidates

Proclara announces start of phase Ib clinical trial of NPT-088 and USD 47 million in new investment

Zebrafish model allows screening of drugs for ARVC8 cardiomyopathy

Sangamo's SB-FIX gene therapy granted FDA orphan drug designation for hemophilia B

Angiotensin-(1-7) receives U.S. orphan drug designation for dystrophic epidermolysis bullosa

Arizona State University discovers novel SIRT3 and ROS production inhibitors

New York Blood Center patents anti-HIV antibody-drug conjugates

Incyte divulges new FGFR-4 inhibitors

Rigel, Bristol-Myers Squibb disclose TGF-beta receptor and/or myostatin inhibitors

Theravance Biopharma presents new neprilysin inhibitors

Promising phase II topline results for sparsentan in focal segmental glomerulosclerosis

Takeda initiates phase III trial of dengue vaccine TAK-003